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Abstract
A n tibod ies  d irec ted  to  the S a antigen are h ighly spec ific  for 
rheum atoid arthritis  (RA) and can be de tec ted  in approxim ately 
4 0 %  of R A  sera. The an tigen , a doub le t o f p ro te in  bands of 
about 50  kDa, is present in p lacen ta  and in RA synovial tissue. 
A lthough it has been s ta ted  that the S a antigen is c itru llina ted 
vim entin, experim ental p roo f fo r th is  cla im  has never been 
pub lished. In th is  study, w e  investigated the prec ise  nature of 
the  antigen. P ep tide  sequences that w ere  ob ta ined  from  highly 
purified  S a antigen w ere  un ique to  vimentin. R ecom binant 
v im entin, however, w as not recogn ized  by anti-S a reference 
sera. In vivo, v im entin  is sub jec ted  to  various post-translational
m odifica tions, inc lud ing  citru llina tion. S ince  an tibod ies  to  
c itru llina ted  p ro te ins  are known to  be h igh ly sp e c ific  fo r RA, we 
investiga ted w he ther Sa is c itru llina ted  and found that Sa 
indeed is c itru llina ted  vimentin. An ti-S a  an tibod ies thus be long 
to  the  fam ily of an tic itru llina ted  p ro te in /p e p tide  antibod ies. The 
p resence of the  Sa antigen in RA synovial tissue , and the 
recent observation  that vim entin  is c itru llina ted  in dying human 
m acrophages, make c itru llina ted  vim entin  an in teresting 
cand idate  autoantigen in RA and may provide new  ins igh ts into 
the  potentia l role of c itru llina ted  synovial an tigens and the 
an tibod ies d irec ted  to  them  in the  pa thophys io logy of RA.
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Introduction
Many autoantibodies, directed against a variety of 
autoantigens, can be detected in the serum of rheumatoid 
arthritis (RA) patients. Most of these autoantibodies 
(reviewed in [1,2]), are also found in patients with other 
diseases and are therefore not specific for RA. Even the 
well known rheumatoid factor (RF) antibodies, directed 
against the Fc part of IgG (reviewed in [3]), are not very 
specific for RA [4,5]. Nevertheless, RF still is the most 
commonly used serological marker for RA. Antibodies 
directed to the Sa antigen have a much higher specificity 
for RA. (This autoimmune system was first described 
using the serum of an RA patient whose name began with 
‘Sa'.) The antibodies target a doublet of protein bands of 
approximately 50 kDa on western blots of extracts from
normal human placenta, spleen, and rheumatoid synovial 
tissue [6].
In a recent review [7], the Sa antigen was suggested to be 
identical to citrullinated vimentin, but data to support that 
statement were not given at that time. In this report, we 
provide such data and show that the Sa antigen is indeed 
citrullinated vimentin. We show that anti-Sa antibodies 
target citrullinated epitopes and not unmodified vimentin, 
which makes them a member of the family of antibodies 
directed to citrullinated proteins (reviewed in [8]). 
Because citrulline, the antigenic determinant for these 
autoantibodies, is a nonstandard amino acid, it is not 
incorporated into proteins during translation. It can, 
however, be generated post-translationally by enzymatic
CCP =  cyclic citrullinated peptide; EGTA =  ethylene glycol bis(ß-aminoethylether) N,N'-tetraacetic acid; IEF =  isoelectric focusing; IP =  immuno- 
precipitation; IPB =  immunoprecipitation buffer; IPB-SDS =  IPB containing 0.1% SDS; MC =  modified citrulline; NP-40 =  Nonidet P40; PAD =  
peptidylarginine deiminase; PBS =  phosphate-buffered saline; pI =  isoelectric point; RA =  rheumatoid arthritis; RF =  rheumatoid factor; s e m  =  stan- 
R142 dard error of the mean; Tris =  tris(hydroxymethyl)aminomethane.
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citrullination (deimination) of arginine residues. This conver­
sion is catalyzed by the enzyme peptidylarginine deiminase 
(PAD, EC 3.5.3.15; reviewed in [9]). Because antibodies to 
citrullinated proteins are very specific for RA, are detectable 
very early in the disease, sometimes even during the preclin- 
ical phase of RA [10,11], and are able to predict clinical 
disease outcome [12-14], it is likely that these antibodies 
will become progressively more valuable for the clinician.
We discuss the new perspective provided by our observa­
tion that Sa is citrullinated vimentin on the potential role of 
citrullinated antigens and the antibodies directed to them 
in RA pathophysiology.
Materials and methods
Patient sera and antibodies
In this study, we used 87 serum samples from patients 
attending the Rheumatic Diseases Unit, Faculté de Medi­
cine, Université de Sherbrooke, Sherbrooke, QC, Canada. 
Sixty-one sera were from RA patients satisfying the 1987 
American Rheumatism Association criteria for the classifi­
cation of RA [15]: of these, 46 were anti-Sa-positive and 
15, anti-Sa-negative. The 26 non-RA sera (8 osteoarthritis 
patients, 14 systemic lupus erythematosus patients, 2 
psoriatic arthritis patients, and 2 healthy individuals) were 
all anti-SA negative. Experiments were approved by the 
the ethics committee of the Université de Sherbrooke.
Rabbit antibodies directed against chemically modified cit- 
rulline (anti-MC) were described previously [16,17]. Mouse 
monoclonal antibodies (RV202) [18] and affinity-purified 
rabbit polyclonal antibodies against vimentin were a kind 
gift of Dr F Ramaekers (Maastricht, The Netherlands).
Preparation of placental Sa antigen
Semipurified placental extracts were prepared as 
described previously [6,19]. Briefly, fresh human placenta 
was homogenized in a low-salt Tris buffer (50 mM 
Tris-HC l (pH 7.4), 120mM NaCl, 0.02% NaN3, 1 mM 
dithiothreitol, 1.5 mM phenylmethylsulfonyl fluoride (PMSF), 
and 0.5 |j,g/ml each of chemostatin, leupeptin, antipain, 
and pepstatin). The soluble fraction was separated by 
anion-exchange chromatography. Sa proteins were eluted 
with 300 mM of NaCl and subsequently desalted and 
lyophilized for storage at -80°C .
Characterization of placental Sa antigen
To prepare Sa for amino acid sequencing, a three-step 
purification procedure was performed essentially as 
described by Liang and colleagues [20]. In the first step,
1 mg of the semipurified Sa (prepared as described above) 
was resolved on a preparative 10% SDS-polyacrylamide 
gel. Vertical strips were cut from each side of the gel and 
were blotted onto nitrocellulose membrane. The blotted 
strips were incubated with anti-Sa reference serum and 
served to determine the exact position of the Sa bands.
In the second step of the procedure, the Sa-rich horizontal 
strip was cut out of the preparative gel and washed exten­
sively in a freshly prepared, filtered and prewarmed (37°C) 
wash solution (2 mM Tris-HCl [pH 8.0], 8 M deionized urea, 
and 1% Nonidet P40 [NP-40]). The washed gel strip was 
then loaded on an isoelectric focusing (IEF) gel (6 M urea, 
1% NP-40, 6% acrylamide [39:1], 2% carrier ampholytes 
[BioRad, Hercules, CA, USA] [pH range 3 -1 0 ] and
0.067% riboflavin). IEF was performed as described by 
Bouffard and colleagues [21]. IEF standards for pH range 
3 .6-6.6  (Sigma, St Louis, MO, USA) were used to esti­
mate the pI of the proteins. Immediately after migration, the 
gel was fixed in 20% trichloroacetic acid (TCA) for 20 min 
and then colored with Coomassie brilliant blue. Each indi­
vidual band was cut out and frozen at -20°C .
The third step of the procedure was to load excised bands 
on a second preparative 10% SDS-polyacrylamide gel. 
Each band from the IEF gel was divided over two lanes: one 
was used for western blotting with anti-Sa reference serum 
to determine the exact position of the Sa antigen, and the 
other was stained with Coomassie brilliant blue. The bands 
that matched the Sa antigen were excised from the 
Coomassie-stained gel and washed twice with 50% ace­
tonitrile before being frozen and sent for microsequencing 
to the Harvard microchemistry facility (Harvard University, 
Cambridge, MA, USA) [22]. Peptides, generated by in-gel 
digestion with trypsin, were separated by liquid chromatog­
raphy followed by double mass spectrometry (LC/MS/MS) 
and finally sequenced by Edman degradation. The obtained 
peptide sequences were used to identify the purified Sa 
antigen using the US National Center for Biotechnology 
Information (NCBI) nonredundant protein database.
Detection of autoantibodies
The presence of anti-Sa antibodies was determined by 
immunoblotting as described previously [6,19]. Briefly, 
semipurified Sa was loaded on 15% SDS-polyacrylamide 
slab gels (0.1-0.2 mg total protein per centimeter of gel 
width). After migration, proteins were blotted onto nitro­
cellulose membranes. Sera were diluted 1:40 and tested 
for IgG anti-Sa. Immunoblots were scored independently 
by two individuals.
Anti-CCP (cyclic citrullinated peptide) autoantibodies 
were detected using the Rapscan RA mk2 kit (CCP2; 
Euro-Diagnostica, Arnhem, The Netherlands) in accor­
dance with the instructions of the manufacturer.
Immunoprecipitation
Immunoprecipitations (IPs) were performed essentially as 
described elsewhere [23]. Briefly, 2.5 mg of semipurified 
Sa was dissolved by heating to 95°C for 1 min in 250 |jJ 
buffer containing 20 mM Tris-HC l (pH 7.4), 20 mM ethyl­
ene glycol bis(ß-aminoethylether) N,N'-tetraacetic acid 
(EGTA), 1 mM dithioerythritol, and 2% SDS. Insoluble pro- R143
Arthritis Research & Therapy Vol 6 No 2 Vossenaar et al.
teins were removed by centrifugation for 5 min at 13,000 g. 
The supernatant was diluted with IP buffer (IPB: 50 mM 
Tris-HC l (pH 7.2), 150mM NaCl, 0.25% sodium deoxy- 
cholate, 1% Triton X-100, and Complete protease 
inhibitor cocktail [Roche Diagnostics, Mannheim, 
Germany]) to a final concentration of 0.1% SDS. The 
diluted solution was centrifuged for another 5 min at
13,000 g  to remove insoluble proteins. Protein G agarose 
beads (150 |jJ 50% slurry) were washed three times with 
IPB-SDS (IPB containing 0.1% SDS). RV202 mono­
clonal antivimentin antibodies (150 |jJ) were incubated 
with the beads in IPB-SDS for 4 hours at room tempera­
ture. After removal of unbound antibody by three washes 
with IPB-SDS, 500 mg Sa (1 ml of diluted solution) was 
incubated with the beads overnight at 4°C. After extensive 
washing (three washes with IPB-SDS, one wash with 
IPB-SDS supplemented with 100mM KCl, and a last 
wash with IPB-SDS), bound proteins were eluted by 
boiling in SDS-sample buffer (250 mM Tris-HCl [pH 6.8], 
2% SDS, 5% ß-mercaptoethanol). The immunoprecipitate 
was divided over three 13% SDS-polyacrylamide gels 
and transferred to Hybond-C Extra membranes (Amer- 
sham Biosciences, Little Chalfont, Buckinghamshire, UK). 
The blots were stained with either anti-MC antibodies, 
anti-Sa reference serum, or polyclonal antivimentin anti­
bodies, as described below. As a negative control, an IP 
was performed with an isotype-matched, unrelated control 
antibody (4G3 directed to U2 snRNP B " protein [24]).
Citrullination of vimentin
Human recombinant vimentin (Research Diagnostics Inc, 
Flanders, NJ, USA) was citrullinated in vitro by rabbit 
muscle PAD (Sigma; 40 U of PAD per milligram of 
vimentin) for 3 hours at 55°C in a buffer containing 0.1 M 
Tris-HC l (pH 7.6), 10 mM CaCl2, and 5 mM dithioerythri- 
tol. The reaction was stopped by adding EGTA (pH 8.0) to 
a final concentration of 50 mM. The extent of the citrullina- 
tion was estimated by immunoblotting with anti-MC anti­
bodies (described below).
Western blotting
Blots were incubated in blocking buffer (PBS containing 
5% nonfat dried milk and 0.1% NP-40) for 1 hour at room 
temperature and 1 -3  hours with the antibody of interest 
diluted in blocking buffer. After washing the blot with 
blocking buffer, bound antibodies were detected by incu­
bation with horseradish-peroxidase-conjugated secondary 
antibodies, followed by chemiluminescence. For the 
detection of citrullinated proteins, blots were chemically 
treated before immunostaining with anti-MC antibodies, as 
described previously [16].
Results
Characterization of the Sa antigen
Antibodies directed to Sa are highly specific for RA. To 
R144 investigate the identity of the Sa antigen, we performed a
Figure 1
Purification of placental Sa antigen. The antigen was purified by anion­
exchange chromatography from extracts of placenta and subsequently 
purified by two-dimensional gel electrophoresis according to a three- 
step procedure described by Liang and colleagues [20]. First, proteins 
were separated by molecular weight, then proteins of appropriate 
molecular weight were separated by isoelectric focusing (IEF), and 
finally proteins with appropriate pI were separated once more by 
molecular weight. Each step of the procedure was monitored by 
western blotting with an anti-Sa reference serum. Shown here is the 
final gel, which was stained with Coomassie brilliant blue. The double 
band in lane 2 is the Sa antigen that was cut out and used for 
microsequencing. Each lane represents a portion of the IEF gel 
(approximate pI is listed above each lane).
multistep purification procedure as described in Materials 
and methods. The accuracy of each step of the procedure 
was monitored by immunoblotting using anti-Sa reference 
serum. The result of final purification is shown in Fig. 1, 
where the estimated molecular weight of Sa is ~50 kDa 
and its pI is 5.0. Two peptide sequences were obtained 
(indicated in Fig. 2; peptide 7 2 -86  was obtained twice) 
that uniquely matched the sequence of vimentin. The cal­
culated molecular weight (54 kDa) and pI (5.1) of vimentin 
closely resemble those of Sa.
Discordance between anti-Sa and anti-unmodified 
vimentin but strong concordance between anti-Sa and 
anti-CCP status
To confirm that Sa is vimentin, we prepared immunoblots 
containing human recombinant vimentin. Antivimentin 
reactivity was observed at lower serum dilutions in only a 
subset of the patients, irrespective of their anti-Sa or 
disease status (results not shown). Concordance between 
reactivity to Sa and reactivity to vimentin was thus not 
observed. Vimentin is known to undergo several post- 
translational modifications, including phosphorylation and 
citrullination [25,26]. Since antibodies directed to citrulli- 
nated proteins are very specific for RA [1], we investigated 
whether anti-Sa sera are reactive with citrullinated epi­
topes. The vast majority (96%) of anti-Sa-positive RA 
patients tested positive for anti-CCP2, using the CCP2 
test kit, as did a substantial proportion (60%) of the anti­
Sa-negative RA patients. Anti-SA-negative RA sera had 
significantly lower anti-CCP2 titers than anti-Sa-positive 
sera (Fig.3). These results suggest that anti-Sa sera 
contain antibodies that are reactive with citrullinated epi­
topes.
Available online http://arthritis-research.com/content/6/2/R142
Figure 2 Figure 3
1 mstRsvssss 
61 yatRssavRl 
121 vRfleqqnki 
181 dimRlReklq 
241 eiqelqaqiq 
301 aanRnndalR 
361 tigRlqdeiq 
421 lnlRetnlds
yRRmfggpgt asRpsssRsy vttstRtysl gsalRpstsR slyasspggv 
R|ssvpgvRll qdsvdf|slad aintefkntR tnekvelqel ndRfanyidk 
llaeleqlkg qgksRlgdly eeemRelRRq vdqltndkaR veveRdnlae
eemlqReeae ntlqsfRqdv dnaslaRldl eRkveslqee iaflkklhee
eqhvqidvdv skpdltaalR dvRqqyesva ak|§ilqeaeew yki|kfadlse
qakqesteyR Rqvqsltcev dalkgtnesl eRqmRemeen faveaanyqd 
nmkeemaRhl Reyqdllnvk maldieiaty RkllegeesR islplpnfss 
lplvdthskR tfliktvetR dgqvinetsq hhddle
Amino acid sequence of vimentin with Sa microsequences and 
sequence of human vimentin (Swiss-Prot database number P08670). 
Two distinct peptides that were obtained by microsequencing are 
indicated in grey. Peptide 7 2 -8 6  was obtained twice, VD84-85 was 
ambiguous in one of the peptides, and R78 could not be sequenced in 
both peptides. All arginines are given in capital and bold, because they 
can potentially be modified to citrulline by peptidylarginine deiminase.
The placental Sa antigen is citrullinated vimentin
To investigate whether Sa is citrullinated vimentin, we used 
a method to detect citrullinated proteins in cell extracts or 
fixed cells. In this method, the citrulline sidechain is specifi­
cally modified by chemical treatment into complex struc­
tures that are so bulky that the influence of flanking amino 
acids for epitope recognition becomes negligible 
[16,17,26-28]. Citrullinated proteins are detected (after 
chemical treatment) by antibodies specifically targeting 
those modified citrullines (anti-MC). Noncitrullinated pro­
teins cannot be modified by the chemical treatment and are 
thus not recognized by the specific antibodies.
We prepared three identical immunoblots (Fig. 4) contain­
ing semipurified placental Sa antigen, human recombinant 
vimentin, and human recombinant vimentin that had been 
citrullinated in vitro. The Sa antigen was recognized by 
anti-Sa reference serum, by antivimentin antibodies, and 
by anti-MC antibodies (lanes 1, 4, and 7, respectively), 
indicating that the antigen is indeed citrullinated vimentin. 
Furthermore, citrullinated vimentin was recognized by the 
anti-Sa serum, whereas unmodified vimentin was not 
(lanes 3 and 2, respectively), indicating that the presence 
of citrulline residues is essential for the autoantigenicity of 
vimentin. The differences in the positions of the bands can 
be attributed to the extent of post-translational processing. 
Data in the literature show decreased mobilities with 
increased citrullination of filaggrin and trichohyalin [29]. 
Furthermore, the increased mobility of the Sa antigen in 
comparison with the recombinant proteins may be the 
result of partial proteolytic processing, as this has been 
described for keratins in the cornified layer of the epider­
mis [30-32 ].
In addition, we performed IP experiments. Vimentin was 
immunoprecipitated from the semipurified Sa preparation 
with monoclonal antivimentin antibody. Immunoprecipi- 
tated vimentin was stained both by anti-MC antibodies 
and by anti-Sa reference serum (Fig. 5), confirming that 
citrullinated vimentin is the antigenic Sa protein.
Comparison of anti-CCP titers in Sa+ and Sa-  patients. To investigate 
a possible relationship between anti-Sa and anti-CCP autoantibodies, 
we compared anti-CCP2 antibody titers in 46 anti-Sa-positive 
rheumatoid arthritis (RA) sera, 15 anti-Sa-negative RA sera, and 26 
control sera, using the CCP2 test kit. Ninety-six percent of anti-Sa- 
positive RA patients, 60% of Sa-negative RA-patients, and none of the 
control patients was positive for anti-CCP2. Anti-Sa-positive RA sera 
had a significantly higher anti-CCP titer (852 ±  96 U; mean ±  s e m ) 
than anti-SA-negative sera (263 ±  110 U) (P <  0.0005; 
Mann-Whitney test). None of the control sera tested positive in either 
of the two assays (12 ±  0.4 U).
Discussion
Autoantibodies against the placental Sa antigen were 
described for the first time over a decade ago [6]. Since 
then, this autoimmune system has proven to be highly spe­
cific for RA in populations of patients from Europe, America, 
and Asia [7]. The mean sensitivity of the assay is 37% 
(range 21-43% ) with 98% specificity (range 92-100% ) 
and a positive predictive value between 95 and 99% [7].
Although it was previously suggested that Sa might be 
identical to citrullinated vimentin [7], evidence for this 
statement has not been published. This had led to confu­
sion in the literature regarding the exact nature of the 
antigen. Indeed, it was proposed that Sa could be identi­
cal to the glycolytic enzyme a-enolase [33] or to calpa- 
statin [34], the natural inhibitor of calpains. Both types of 
autoantibody, however, turned out to be independent 
autoimmune systems, associated with but not specific for 
RA [35,36]. Other workers have claimed that apolipopro- 
tein-A-1-binding protein could be (part of) the Sa antigen
[37]. More recently, autoantibodies not specific for RA 
and directed to a 68-kDa placental protein were reported
[38]. Nevertheless, the authors of that study still chose, 
inappropriately, to label this antigen Sa. We thus deemed 
it important to report the experimental evidence relating to 
the exact nature of the Sa antigen. R145
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F igu re  4 Figure 5
Placental Sa antigen is citrullinated vimentin. Three identical 
immunoblots containing semipurified placental Sa antigen (100 mg; 
lanes 1, 4, 7), human recombinant vimentin (Vim) (50 ng; lanes 2, 5, 8), 
and human recombinant vimentin that had been citrullinated in vitro 
(cit-Vim) (50 ng; lanes 3, 6 , 9) were stained with either anti-Sa 
reference serum (left panel), anti-modified citrulline (anti-MC) 
antibodies (middle panel), or antivimentin (anti-Vim) antibodies (right 
panel). Sa antigen is recognized both by anti-MC antibodies and by 
anti-Vim antibodies (lanes 4 and 7, respectively), indicating that the 
antigen is indeed citrullinated vimentin. Citrullinated vimentin was 
recognized by the anti-Sa serum, whereas unmodified vimentin was not 
(lanes 3 and 2, respectively), indicating that the presence of citrulline 
residues is essential for the autoantigenicity of Sa. Molecular weight 
markers are indicated on the left.
We obtained several peptide sequences from highly puri­
fied preparations of Sa antigen that were unique to the 
intermediate filament protein vimentin. Autoantibodies 
directed to vimentin were described many years ago in RA
[39] as well as in other autoimmune diseases [39,40], in 
infectious diseases [41,42], and even in healthy individu­
als [43]. Those antivimentin autoantibodies, which are 
mainly of the IgM class, are not specific for RA. In con­
trast, anti-Sa antibodies are highly specific for RA and are 
predominantly IgG [6].
Here, using recombinant human vimentin, we found IgG 
antivimentin antibodies in only a few sera. The antibodies 
were only found in low titers, were not related to anti-Sa 
positivity, and had no disease specificity. Thus we con­
clude that anti-Sa sera do not target native (unmodified) 
vimentin.
Many known autoantibodies are directed against proteins 
that become modified during cell death and in particular 
during apoptosis (reviewed in [44,45]). These modifica­
tions include proteolytic cleavage by caspases or 
granzyme B [46], transglutamination [47], (de)phosphory- 
lation [48,49], and also citrullination [26,50]. When these 
modified self proteins are inefficiently cleared, they may be 
presented to the immune system and might be recognized 
as ‘nonself' [51]. If sufficient ‘danger signals' are present 
(as in an inflammatory environment), this can lead to an
Antivimentin (anti-Vim) can immunoprecipitate Sa antigen from 
placental extract. Vimentin was immunoprecipitated from semipurified 
placental extract with monoclonal antibody RV202 (lanes 3). 
Immunoprecipitated vimentin was stained by anti-modified citrulline 
(anti-MC) antibodies (upper panel), anti-Sa serum (middle panel), or 
polyclonal antivimentin (anti-Vim) antibodies (lower panel), indicating 
that Sa is citrullinated vimentin. An immunoprecipitation (IP) with an 
isotype-matched monoclonal control antibody 4G3 (lanes 4) served as 
a negative control. Lanes 1 contain human recombinant vimentin 
citrullinated in vitro (cit-Vim) (50 ng) as a positive control. Lanes 2 
show 10% input . Molecular weight markers are indicated on the left.
immune response against the modified proteins [51,52]. 
Vimentin can be subjected to various post-translational 
modifications that could be important for its autoantigenic­
ity. Those modifications are not present in the recombinant 
vimentin, and this fact could readily explain why we did not 
observe significant antivimentin reactivity in anti-Sa-posi- 
tive patients.
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Intermediate filaments are a major component of the 
cytoskeleton of eukaryotic cells. Together with the actin 
microfilaments and microtubules, they form an integrated 
network that is responsible for the mechanical integrity of 
the cell and is critically involved in processes such as cell 
division, motility, and plasticity. Although there are at least 
five distinct classes of intermediate filament, cells of mes­
enchymal origin and most cells in culture contain interme­
diate filaments composed of vimentin. Vimentin 
intermediate filaments are dynamic structures [53] and 
their flexible organization is important for various cellular 
processes [54]. The filaments are composed of homopoly­
mers of vimentin subunits [55]. The polymerization of the 
free subunits into filaments is a reversible process, in 
which phosphorylation is an important regulating factor; 
free vimentin subunits are more heavily phosphorylated 
(on their amino terminal head domain) than polymerized 
vimentin [25,53]. Vimentin can also be citrullinated, which 
means that some of its arginine residues are deiminated to 
citrulline residues. This modification of vimentin has been 
described as occurring in dying macrophages [26,28]. It 
is known that citrullination of the amino terminal head 
domain by PAD induces disassembly of the vimentin fila­
ments in vitro [50]. Therefore, citrullination may be 
involved in the disassembly of the vimentin cytoskeleton 
during cell death, when the network of vimentin filaments 
collapses into perinuclear aggregates. The phosphoryla­
tion and citrullination of vimentin may account for the small 
differences between calculated and observed molecular 
weight/pI values (53.6/5.1 vs ~50/5.0) and also for the 
differences in gel mobility observed in Fig. 4. Larger varia­
tions in molecular weight/pI values of vimentin have been 
reported elsewhere (66.9/5.6 and 48.6/4.6) [56].
The existence of citrullinated vimentin provided us with 
new clues to the nature of the Sa antigen. Autoantibodies 
directed to citrullinated proteins are highly specific for RA 
(reviewed in [8]). Besides their high specificity, they share 
more features with the anti-Sa antibodies. They can be 
detected very early in the disease and can often predict 
the clinical outcome of the disease [10,57,58]. Further­
more, both types of autoantibody correlate with the pres­
ence of HLA-DR shared epitope [58,59]. To investigate 
whether anti-Sa sera are indeed directed against citrulli- 
nated epitopes, we tested 87 sera of known anti-Sa status 
in the anti-CCP2 assay. Our aim was not to compare the 
two assays, since we did not test large numbers of ran­
domly selected patients, but to investigate the concor­
dance or lack of it between anti-Sa and anti-CCP antibody 
status. Of the anti-Sa-positive RA sera, most were also 
positive for anti-CCP. Of anti-SA-negative RA sera, a con­
siderable proportion was anti-CCP-positive, albeit at a 
lower titer. The anti-CCP titers of anti-Sa-positive patients 
were on average more than three times as high as those of 
anti-Sa-negative RA patients. It thus appears that mainly 
sera that are strongly positive for anti-CCP will score posi­
tive for anti-Sa. This observation is in agreement with the 
difference in sensitivities of the two assays (70-80%  for 
anti-CCP2, 30 -40%  for anti-Sa) [7,8]. Other assays that 
detect anticitrullinated protein antibodies by immunoblot- 
ting (using filaggrin as the antigen) have sensitivities 
(~40%) comparable with the sensitivity of the anti-Sa 
assay [60-62 ].
The presence of antibodies to citrullinated proteins is cor­
related with a more severe disease outcome, especially 
when high titers of the antibody are present (reviewed in
[8]). In an early RA cohort study, the presence of anti-Sa 
antibodies appeared to be slightly more correlated with 
erosive disease outcome than the presence of anti-CCP 
[63], a finding that is in agreement with the idea that the 
Sa antigen is recognized by patients with high titers of 
anticitrullinated protein antibodies.
To actually prove that the placental Sa antigen is citrulli- 
nated vimentin, we performed western blotting and IP 
experiments. Sa was recognized by anti-MC antibodies, 
showing that it does contain citrulline residues. Further­
more, anti-Sa serum was reactive with vimentin citrulli- 
nated in vitro but not with unmodified vimentin, showing 
that citrulline is essential for antigenicity. Finally, antigenic 
Sa protein could be immunoprecipitated from semipurified 
placental extracts by antivimentin antibodies, showing that 
the antigenic citrulline residues are indeed carried by 
vimentin. Taken together, our results show that the placen­
tal Sa antigen is citrullinated vimentin. Therefore, anti-Sa 
antibodies belong to the expanding family of anticitrulli- 
nated protein antibodies (reviewed in [8]), which includes 
antiperinuclear factor [64], anti-‘keratin' antibodies [65], 
antifilaggrin antibodies [66,67], and anti-CCP antibodies 
[68,69]. Their common antigenic determinant is the non­
standard amino acid citrulline; the name of the antibody is 
simply determined by the antigen used to detect them.
Not every citrulline residue in a protein will provide a good 
epitope, however, because the amino acids flanking the 
citrulline residue are important for the presentation of the 
antigenic citrulline residue. Therefore, proteins with a high 
arginine content, such as filaggrin, fibrinogen, vimentin, 
histones, or myelin basic protein, are more likely to contain 
reactive epitopes upon citrullination than are proteins with 
low arginine content, such as albumin [70]. In fact, most of 
the in vitro-citrullinated arginine-rich proteins mentioned 
here have been used in diagnostic assays to detect the RA 
specific anticitrullinated protein antibodies (filaggrin 
[62,71], fibrinogen [72], myelin basic protein [70]). 
Because each antigen and each test format (immunofluo­
rescence, immunoblot, or ELISA) will show different values 
for sensitivity and specificity for RA, care should be taken in 
using the proper nomenclature and standardization.
The commercially available anti-CCP2 test has a reported 
sensitivity of almost 80%  and a specificity of 98% [73,74]. R147
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Interestingly, some (2 of 46) of the anti-Sa-positive RA 
patients tested negative for anti-CCP. Vimentin contains 
43 arginine residues (see Fig. 2). Each of them can poten­
tially be citrullinated by PAD, resulting in a large variety of 
citrullinated epitopes. In contrast, in the anti-CCP2 test 
only a few epitopes are presented. It had been previously 
established that RA sera show a remarkable variety in the 
reactivity pattern towards different citrulline-containing 
peptides, indicating, as previously mentioned, that the 
amino acids flanking the citrulline residue are important for 
the antigenicity of the epitope and that anticitrullinated 
protein reactivity is a strongly polyclonal response [68]. It 
follows that anti-Sa-positive/anti-CCP-negative sera are 
most likely directed to citrullinated epitopes that are 
present only on the Sa antigen.
Conclusion
The placental Sa antigen specifically recognized by anti­
bodies in serum from RA patients has been identified as 
citrullinated vimentin. Anti-Sa antibodies, therefore, belong 
to the family of anticitrullinated protein antibodies. The Sa 
antigen is present in the rheumatoid pannus [6]. We 
recently observed that vimentin is citrullinated in dying 
human macrophages [28]. Furthermore, it has been 
reported that vimentin-derived citrullinated peptides were 
able to bind to HLA-DR4 shared epitope much more effi­
ciently than noncitrullinated peptides [75]. These findings, 
together with our identification of the Sa antigen, make cit- 
rullinated vimentin an interesting candidate autoantigen in 
RA and may provide new insights into the potential role of 
citrullinated synovial antigens and the antibodies directed 
to them in the pathophysiology of RA.
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